Roth MKM Reinstates Buy on iRadimed, Announces $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
Roth MKM analyst Jason Wittes has reinstated iRadimed (NASDAQ:IRMD) with a Buy rating and set a price target of $65.
April 22, 2024 | 1:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Roth MKM reinstates iRadimed with a Buy rating and a $65 price target, indicating a positive outlook on the stock.
The reinstatement of a Buy rating by a reputable analyst firm like Roth MKM, coupled with a significant price target of $65, suggests a strong bullish sentiment towards iRadimed. This endorsement is likely to instill confidence among investors, potentially driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100